PDF(Pubmed)
Abstract：
UNASSIGNED: This study aims to describe the clinical characteristics, disease activity, and structural damage in patients with axial spondyloarthritis (axSpA) who receive chronic treatment with nonsteroideal anti-inflammatory drugs (NSAIDs) or advanced therapies in a clinical setting.
UNASSIGNED: Cross-sectional study on axSpA patients consecutively recruited from the outpatient clinic of a tertiary hospital. We collected data on clinical and demographic characteristics, as well as treatment patterns involving NSAIDs and advanced therapies. Structural damage was assessed using mSASSS.
UNASSIGNED: Overall, data from 193 axSpA patients (83% ankylosing spondylitis) were gathered, with a mean disease duration of 21.4 years. Of these, 85 patients (44%) were exclusively taking NSAIDs, while 108 (56%) were receiving advanced therapies, with TNF inhibitors being the predominant choice (93 out of 108, 86.1%). Among patients using NSAIDs, 64.7% followed an on-demand dosing regimen, while only 17.6% used full doses. Disease activity was low, with a mean BASDAI of 3.1 and a mean ASDAS-CRP of 1.8. In comparison to patients under chronic NSAID treatment, those taking advanced therapies were primarily male (69.4% versus 51.8%, p = 0.025) and significantly younger (mean age of 49 versus 53.9 years, p = 0.033). Additionally, patients on advanced therapies exhibited lower ASDAS-CRP (p = 0.046), although CRP serum levels and BASDAI scores did not differ between the two groups. In the multivariable analysis, therapy (NSAID versus biological treatment) was not independently associated with ASDAS-CRP, BASDAI or mSASSS.
UNASSIGNED: This cross-sectional analysis of a real-world cohort of axSpA patients shows positive clinical and radiological outcomes for both NSAIDs and advanced therapies.
UNASSIGNED: Cross-sectional study on axSpA patients consecutively recruited from the outpatient clinic of a tertiary hospital. We collected data on clinical and demographic characteristics, as well as treatment patterns involving NSAIDs and advanced therapies. Structural damage was assessed using mSASSS.
UNASSIGNED: Overall, data from 193 axSpA patients (83% ankylosing spondylitis) were gathered, with a mean disease duration of 21.4 years. Of these, 85 patients (44%) were exclusively taking NSAIDs, while 108 (56%) were receiving advanced therapies, with TNF inhibitors being the predominant choice (93 out of 108, 86.1%). Among patients using NSAIDs, 64.7% followed an on-demand dosing regimen, while only 17.6% used full doses. Disease activity was low, with a mean BASDAI of 3.1 and a mean ASDAS-CRP of 1.8. In comparison to patients under chronic NSAID treatment, those taking advanced therapies were primarily male (69.4% versus 51.8%, p = 0.025) and significantly younger (mean age of 49 versus 53.9 years, p = 0.033). Additionally, patients on advanced therapies exhibited lower ASDAS-CRP (p = 0.046), although CRP serum levels and BASDAI scores did not differ between the two groups. In the multivariable analysis, therapy (NSAID versus biological treatment) was not independently associated with ASDAS-CRP, BASDAI or mSASSS.
UNASSIGNED: This cross-sectional analysis of a real-world cohort of axSpA patients shows positive clinical and radiological outcomes for both NSAIDs and advanced therapies.
摘要：
■本研究旨在描述临床特征，疾病活动,在临床上接受非甾体类抗炎药（NSAIDs）或高级治疗的轴向脊柱关节炎（axSpA）患者的结构损伤。
■从三级医院门诊连续招募的axSpA患者的横断面研究。我们收集了临床和人口统计学特征的数据，以及涉及NSAIDs和先进疗法的治疗模式。使用mSASSS评估结构损伤。
■总的来说，从193名axSpA患者（83％的强直性脊柱炎）的数据收集，平均病程为21.4年。其中,85名患者（44%）仅服用NSAIDs，108人（56%）正在接受先进的治疗，TNF抑制剂是主要选择（108个中的93个，占86.1％）。在使用NSAIDs的患者中，64.7%遵循按需给药方案，而只有17.6%的人使用全剂量。疾病活动低，平均BASDAI为3.1，平均ASDAS-CRP为1.8。与接受慢性NSAID治疗的患者相比，接受高级疗法的人主要是男性(69.4%对51.8%，p=0.025)和显著年轻(平均年龄49岁对53.9岁，p=0.033)。此外,接受高级治疗的患者表现出更低的ASDAS-CRP(p=0.046)，尽管CRP血清水平和BASDAI评分在两组之间没有差异。在多变量分析中，治疗（NSAID与生物治疗）与ASDAS-CRP无关，BASDAI或mSASSS。
对axSpA患者现实队列的横断面分析显示，NSAIDs和先进疗法的临床和放射学结果均为阳性。
■从三级医院门诊连续招募的axSpA患者的横断面研究。我们收集了临床和人口统计学特征的数据，以及涉及NSAIDs和先进疗法的治疗模式。使用mSASSS评估结构损伤。
■总的来说，从193名axSpA患者（83％的强直性脊柱炎）的数据收集，平均病程为21.4年。其中,85名患者（44%）仅服用NSAIDs，108人（56%）正在接受先进的治疗，TNF抑制剂是主要选择（108个中的93个，占86.1％）。在使用NSAIDs的患者中，64.7%遵循按需给药方案，而只有17.6%的人使用全剂量。疾病活动低，平均BASDAI为3.1，平均ASDAS-CRP为1.8。与接受慢性NSAID治疗的患者相比，接受高级疗法的人主要是男性(69.4%对51.8%，p=0.025)和显著年轻(平均年龄49岁对53.9岁，p=0.033)。此外,接受高级治疗的患者表现出更低的ASDAS-CRP(p=0.046)，尽管CRP血清水平和BASDAI评分在两组之间没有差异。在多变量分析中，治疗（NSAID与生物治疗）与ASDAS-CRP无关，BASDAI或mSASSS。
对axSpA患者现实队列的横断面分析显示，NSAIDs和先进疗法的临床和放射学结果均为阳性。
